転移性ホルモン感受性前立腺癌における ADT に加えてのダロルタミドと ADT の比較 (ARANOTE)
転移性ホルモン感受性前立腺癌(mHSPC)の男性における、アンドロゲン除去療法(ADT)に加えてダロルタミドとプラセボと ADT を併用した無作為化二重盲検プラセボ対照第 III 相試験
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Chandigarh、インド、160012
- Post Graduate Institute of Medical Education and Research
-
Kolkata、インド、700156
- Tata Medical Center
-
Nashik、インド、422009
- Apex Wellness Hospital
-
New Delhi、インド、110 085
- Rajiv Gandhi Cancer Institute & Research Centre
-
-
Andhra Pradesh
-
Visakhapatnam、Andhra Pradesh、インド、530017
- Mahatma Gandhi Cancer Hospital & Research Institute
-
-
Gujarat
-
Ahmedabad、Gujarat、インド、380016
- The Gujarat Cancer & Research Institute
-
Ahmedabad、Gujarat、インド、380060
- HCG Cancer Centre - Ahmedabad
-
Vadodara、Gujarat、インド、390007
- Cancer Care Clinic - Vadodara
-
-
Karnataka
-
Belagavi、Karnataka、インド、590010
- K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
-
Bengaluru、Karnataka、インド、560027
- Healthcare Global Enterprises Ltd
-
-
Kerala
-
Kochi、Kerala、インド、682 041
- Amrita Institute of Medical Sciences
-
Thiruvananthapuram、Kerala、インド、695011
- Regional Cancer Centre - Thiruvananthapuram
-
-
Maharashtra
-
Chhatrapati Sambhajinagar、Maharashtra、インド、431001
- Marathwada Regional Cancer Centre and Research Institute
-
Mumbai、Maharashtra、インド、400026
- Jaslok Hospital and Research Centre
-
Nashik、Maharashtra、インド、422004
- Curie Manavata Cancer Centre
-
Pune、Maharashtra、インド、411001
- Jehangir Hospital
-
-
Odisha
-
Bhubaneswar、Odisha、インド、751019
- All India Institute of Medical Sciences
-
Bhubaneswar、Odisha、インド、751007
- Sparsh Hospital & Critical Care
-
-
Puducherry
-
Gorimedu、Puducherry、インド、605006
- Jawaharlal Institute Of Postgraduate Medical Education and R
-
-
Punjab
-
Ludhiana、Punjab、インド、141008
- Christian Medical Center & Hospital
-
-
Rajasthan
-
Jaipur、Rajasthan、インド、302017
- Sawami Man Singh (SMS) Medical College & Attached Hospitals
-
-
Tamil Nadu
-
Madurai、Tamil Nadu、インド、625020
- Apollo Speciality Hospitals
-
Madurai、Tamil Nadu、インド、625107
- Meenakshi Mission Hospital & Research Centre
-
-
-
-
-
Cherkasy、ウクライナ、18009
- CNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of the Cherkasy Regional Council"
-
Dnipro、ウクライナ、49102
- City Dnipropetrovsk Multi- field Clinical Hosp. 4 DSMA
-
Kyiv、ウクライナ、4107
- Kyiv Regional Oncological Dispensary
-
Kyiv、ウクライナ、02660
- Kyiv City Hospital #3 - Department of Urology
-
-
-
-
New South Wales
-
Kingswood、New South Wales、オーストラリア、2747
- Nepean Hospital
-
St Leonards、New South Wales、オーストラリア、2065
- Northern Cancer Institute
-
Sydney、New South Wales、オーストラリア、2109
- Macquarie University Hospital - Oncology Department
-
-
South Australia
-
Adelaide、South Australia、オーストラリア、5000
- Cancer Research South Australia
-
-
Victoria
-
Frankston、Victoria、オーストラリア、3199
- Peninsula Oncology Centre
-
Heidelberg、Victoria、オーストラリア、3084
- Austin Health
-
-
-
-
Ontario
-
Burlington、Ontario、カナダ、L7N 3V2
- G. Kenneth Jansz Medicine Professional Corporation
-
-
Quebec
-
Montreal、Quebec、カナダ、H2X 0A9
- Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
-
-
-
-
-
Barcelona、スペイン、08025
- Fundacio Puigvert | Urologia
-
Barcelona、スペイン、08208
- Parc Tauli Hospital Universitari | Oncologia
-
Cáceres、スペイン、10003
- Hospital San Pedro De Alcantara | Oncologia
-
Málaga、スペイン、20910
- Hospital Universitario Virgen De La Victoria | Urologia
-
Seville、スペイン、41013
- Hospital Universitario Virgen Del Rocio S.L. | Urologia
-
-
Madrid
-
Alcorcón、Madrid、スペイン、28922
- Hospital Universitario Fundacion Alcorcon | Urologia
-
-
-
-
-
Santiago、チリ、7510032
- Oncovida
-
Santiago、チリ
- UROMED
-
Santiago、チリ、TBC
- Hospital Clínico de la Pontificia Univ. Católica de Chile
-
Santiago、チリ、7500921
- Fundación Arturo López Perez
-
-
Araucania
-
Temuco、Araucania、チリ、4781156
- Centro de Investigación Clínica del Sur
-
-
Santiago Metropolitan
-
Providencia、Santiago Metropolitan、チリ、7500653
- Centro de Estudios Clínicos SAGA SpA
-
-
Valparaiso
-
Viña del Mar、Valparaiso、チリ、2520598
- OncoCentro
-
-
-
-
Bay of Plenty
-
Tauranga、Bay of Plenty、ニュージーランド、3112
- Tauranga Urology Research Limited
-
-
Canterbury
-
Christchurch、Canterbury、ニュージーランド、8013
- Canterbury Urology Research Trust
-
-
Waikato Region
-
Hamilton、Waikato Region、ニュージーランド、3240
- Waikato Hospital
-
-
-
-
-
Rio de Janeiro、ブラジル、22793-080
- Instituto COI de Educação e Pesquisa
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、ブラジル、41950-640
- Assistência Multidisciplinar em Oncologia (AMO)
-
-
Goiás
-
Goiânia、Goiás、ブラジル、74605-070
- Hosp. Araujo Jorge da Associação de Combate ao Câncer
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、ブラジル、30130-100
- Hospital da Universidade Federal de Minas Gerais
-
Belo Horizonte、Minas Gerais、ブラジル、30150-270
- Cetus Oncologia Hospital Dia
-
-
Paraná
-
Curitiba、Paraná、ブラジル、81520-060
- Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、ブラジル、59040-000
- Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica
-
-
Rio Grande do Sul
-
Pelotas、Rio Grande do Sul、ブラジル、96020-080
- Unidade de Pesquisas Clinicas em Oncologia
-
Porto Alegre、Rio Grande do Sul、ブラジル、90850-170
- Hospital Mae de Deus
-
Porto Alegre、Rio Grande do Sul、ブラジル、91350-280
- FZ Pesquisa e Servicos em Cardiologia | Porto Alegre, Brazil
-
Porto Alegre、Rio Grande do Sul、ブラジル、90020-090
- Santa Casa de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia
-
-
São Paulo
-
Barretos/SP、São Paulo、ブラジル、14784-400
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
São José do Rio Preto、São Paulo、ブラジル、15090-000
- Hospital de Base | Funfarme - Centro Integrado de Pesquisa - Cardiologia
-
São Paulo、São Paulo、ブラジル、03102-002
- IBCC - Instituto Brasileiro de Controle do Cancer
-
São Paulo、São Paulo、ブラジル、01243-020
- Urobrasil
-
São Paulo、São Paulo、ブラジル、04039-004
- Inst. de Assistência Médica ao Sérvidor Público Estadual
-
-
-
-
-
Lima、ペルー、LIMA 11
- Hospital Militar Luis Arias Schreiber
-
Lima、ペルー、LIMA 27
- Clínica El Golf
-
-
Lima region
-
San Isidro、Lima region、ペルー、15036
- Aliada
-
Santiago de Surco、Lima region、ペルー、15033
- Hospital Guillermo Almenara Irigoyen
-
-
-
-
-
Daugavpils、ラトビア、LV-5417
- Daugavpils Regional Hospital
-
Riga、ラトビア、1038
- RAKUS Hospital Gailezers
-
Riga、ラトビア、LV-1001
- URO Ltd.
-
Riga、ラトビア、LV-1002
- P. Stradins Clinical University Hospital
-
Valmiera、ラトビア、LV-4201
- Vidzemes Hospital
-
-
-
-
-
Kaunas、リトアニア、LT-50009
- The Hospital of Lithuanian University of Health SciencesLUHS
-
Klaipėda、リトアニア、LT-92288
- PI Klaipedos University Hospital
-
Vilnius、リトアニア、LT-08660
- National Cancer Institute
-
Vilnius、リトアニア、LT-08661
- Vilnius University Hospital Santaros Klinikos
-
-
-
-
-
Arkhangelsk、ロシア、163045
- Arkhangelsk Clinical Oncology Dispensary
-
Chelyabinsk、ロシア、454087
- Chelyabinsk Regional Oncology Dispensary
-
Chelyabinsk、ロシア、454048
- Ltd "EVIMED"
-
Ivanovo、ロシア、153040
- Ivanovo Regional Oncology Dispensary
-
Kazan'、ロシア、420029
- Republican Clinical Oncology Dispensary Kazan
-
Moscow、ロシア、117997
- Research Centre of X-ray and Radiology
-
Nizhny Novgorod、ロシア、603109
- Volga District Med Center FMBA
-
Novosibirsk、ロシア、630099
- LLC Reafan
-
Novosibirsk、ロシア、630099
- Medical Center "Avicenna"
-
Omsk、ロシア、644013
- Clinical Oncological Dispensary of Omsk Region
-
Saint Petersburg、ロシア、196006
- AV Medical Group
-
Saint Petersburg、ロシア、197758
- Russian Scientific Radiology and Surgery Technologies Center
-
Saint Petersburg、ロシア、197758
- Scientific Research Instutute of Oncology n.a. N.N. Petrov
-
Tyumen、ロシア、625041
- Multi-Field Clinical Medical Center "Medical City"
-
Ufa、ロシア、450054
- Republican Clinical Oncology Dispensary
-
Vologda、ロシア、160022
- Vologda Regional Hospital
-
Yekaterinburg、ロシア、620102
- Sverdlovsk Regional Clinical Hospital #1
-
-
-
-
-
Beijing、中国、100142
- Beijing Cancer Hospital
-
Beijing、中国、100083
- Peking University Third Hospital
-
Beijing、中国、100000
- Cancer Hospital, Chinese Academy of Medical Sciences
-
-
Anhui
-
Hefei City, Anhui Province、Anhui、中国、230031
- Anhui Provincial Hospital
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100730
- Beijing Hospital
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510000
- Sun Yat-sen University Cancer Center
-
Guangzhou、Guangdong、中国、510180
- Guangzhou First People Hospital
-
Shenzhen、Guangdong、中国、518172
- Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
-
-
Hubei
-
Wuhan、Hubei、中国、430030
- Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
-
Wuhan、Hubei、中国、430079
- Hubei Cancer Hospital
-
Wuhan、Hubei、中国、430071
- Zhongnan hospital ,Wuhan University
-
-
Hunan
-
Changsha、Hunan、中国、410013
- Hunan Cancer Hospital - Oncology Department
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
-
Nantong、Jiangsu、中国、226361
- Nantong tumor hospital
-
Suzhou、Jiangsu、中国、215004
- The 2nd Affiliated Hospital of Soochow University
-
-
Jilin
-
Changchun、Jilin、中国、130021
- 1st Hospital of Jilin University
-
-
Liaoning
-
Shengyang、Liaoning、中国、110042
- Liaoning Cancer Hospital and Institute
-
-
Shandong
-
Yantai、Shandong、中国、264000
- Yantai Yuhuangding Hospital
-
-
Shanxi
-
Xi’an、Shanxi、中国、710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu、Sichuan、中国、610072
- SichuanAcademyofMedicalSciences&SichuanProvincialPeople'sHos
-
Chengdu、Sichuan、中国、MISSING
- Sichuan University West China Hospital
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310000
- The 1st Affiliated Hospital of Zhejiang University
-
Hangzhou、Zhejiang、中国、310014
- ZheJiang Provincial People's Hospital
-
Ningbo、Zhejiang、中国、315010
- Ningbo First Hospital
-
Wenzhou、Zhejiang、中国、325000
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Cape Town、南アフリカ、7570
- Cape Town Oncology Trials
-
-
Eastern Cape
-
Port Elizabeth、Eastern Cape、南アフリカ、6045
- Cancercare Langenhoven
-
-
Gauteng
-
Johannesburg、Gauteng、南アフリカ、1475
- East Rand Medical Research Unit
-
Pretoria、Gauteng、南アフリカ、2
- University of Pretoria, Clinical Research Unit
-
-
-
-
-
Changhua、台湾、50006
- Changhua Christian Hospital
-
Taichung、台湾、40705
- Taichung Veterans General Hospital
-
Tainan、台湾、704
- National Cheng Kung University Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
-
Kaohsiung
-
Kaohsiung City、Kaohsiung、台湾、807377
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of prostate
- Metastatic disease
- Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti-androgen, but not earlier than 12 weeks before randomization
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
- Adequate bone marrow, liver and renal function
Exclusion Criteria:
- Prior treatment with: LHRH agonist/antagonists except neoadjuvant and /or adjuvant therapy; Second-generation androgen receptor (AR) inhibitors such as enzalutamide, darolutamide, apalutamide or other investigational AR inhibitors; Cytochrome P17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as anti-cancer treatment for prostate cancer; Chemotherapy including docetaxel or immunotherapy for prostate cancer; Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days prior to randomization; Radiopharmaceuticals; Any other anti-cancer treatment for prostate cancer, excluding local therapies and ADT.
- Treatment with radiotherapy within 2 weeks before randomization
- Contraindication to iodinated CT and gadolinium chelate MRI intravenous contrast agent(s)
- Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)
- Uncontrolled hypertension as indicated by a resting systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite medical management
- A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of study drug
- Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization
- Inability to swallow oral medications
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Darolutamide+ADT
Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy |
Coated tablet, oral administration Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy |
|
プラセボコンパレーター:Placebo+ADT
Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy |
Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy Coated tablet matching Darolutamide in appearance, oral administration |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Radiological Progression-free Survival (rPFS) Assessed by Central Review
時間枠:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:From randomization to the final analysis date, approximately 47 months
|
Time from the date of randomization to the date of death from any cause. |
From randomization to the final analysis date, approximately 47 months
|
|
Time to Castration-Resistant Prostate Cancer (CRPC)
時間枠:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first). |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to Initiation of Subsequent Anti-cancer Therapy
時間枠:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to PSA Progression
時間枠:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level <0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels <0.50 ng/mL is requested at initial assessment. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
PSA Undetectable Rates (<0.2 ng/mL)
時間枠:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values <0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to Pain Progression
時間枠:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale [WPS]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS >0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Number of Participants With Adverse Events as a Measure of Safety
時間枠:From start of study drug administration until 30 days after the last administration
|
An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug. |
From start of study drug administration until 30 days after the last administration
|
協力者と研究者
協力者
協力者
出版物と役立つリンク
一般刊行物
- Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP; ARANOTE Study Investigators. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024 Dec 20;42(36):4271-4281. doi: 10.1200/JCO-24-01798. Epub 2024 Sep 16.
- Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP. Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial. Eur Urol. 2026 Aug 12:S0302-2838(26)02313-4. doi: 10.1016/j.eururo.2026.07.026. Online ahead of print.
- Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2026 May;27(5):614-624. doi: 10.1016/S1470-2045(26)00014-8. Epub 2026 Apr 9.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 21140
- 2020-003093-48 (EudraCT番号)
- 2022-502244-12-00 (その他の識別子:CTIS (EU))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。